Finanzen von Veraxa Biotech AG (VRXA)VRXAVeraxa Biotech AG

Evaluating the bottom line, Veraxa Biotech AG maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 5.72%, provide a clear picture of how effectively VRXA converts its operational activities into shareholder value.

In the context of the broader market, VRXA competes directly with industry leaders such as ALXO and IVVD. With a market capitalization of $134.65M, it holds a significant position in the sector. When comparing efficiency, VRXA's gross margin of N/A stands against ALXO's N/A and IVVD's 91.09%. Such benchmarking helps identify whether Veraxa Biotech AG is trading at a premium or discount relative to its financial performance.

The financial performance shows a concerning trend, with net income dropping significantly in recent quarters, culminating in a net income of only $180,498 in Q1 2026. The current ratio has also fallen to 0.00, indicating potential liquidity issues. However, the company has appointed experienced CFOs recently, which may improve financial management.